Treating brain cancer is especially challenging because the brain is protected by the blood-brain barrier.
While this barrier helps keep harmful substances away from the brain, it also blocks many medicines that doctors would like to use against brain tumours. This is one reason why glioblastoma remains one of the deadliest cancers despite decades of research.
Scientists have now developed a modified form of vitamin B12 that may help solve part of this problem. Their findings were published in Oncoscience after researchers investigated whether the compound, called nitrosylcobalamin or NO-Cbl, could carry a cancer-fighting molecule into brain tumours.
The research team performed experiments using cancer cell lines, rats with glioblastoma and human glioblastoma cells grown in the laboratory. They tracked where the compound travelled in the body, how long it remained inside tumours and whether it improved the effects of current brain cancer treatments.
One of the most important discoveries was that NO-Cbl successfully crossed the blood-brain barrier. After entering the brain, it concentrated mainly inside tumour tissue rather than healthy organs. This selective accumulation is important because it may reduce damage to normal tissue while increasing treatment inside the tumour.
The treatment also continued releasing nitric oxide inside tumour tissue for many hours. Nitric oxide is a signalling molecule that can influence blood flow, inflammation and cell survival. In cancer cells, it may also help trigger cell death and increase the effectiveness of other anti-cancer medicines.
When researchers combined NO-Cbl with temozolomide or TRAIL, the results were much stronger than using any single treatment alone. This suggests the new compound may eventually become part of combination therapy rather than replacing current treatments.
The authors believe NO-Cbl may also help overcome treatment resistance by affecting several biological pathways that allow glioblastoma cells to survive. If confirmed, this could make standard therapies work better against difficult-to-treat tumours.
Despite these encouraging findings, the researchers stressed that this is only the beginning of the development process. Larger animal studies and eventually carefully controlled human clinical trials will be needed before doctors know whether the treatment is safe and effective.
Glioblastoma continues to have very poor survival rates, making new treatment approaches urgently needed. Technologies that improve drug delivery into the brain are attracting growing interest because they could improve not only glioblastoma treatment but also therapies for other neurological diseases.
The greatest strength of this study is that it tackles the blood-brain barrier, one of the biggest challenges in neuro-oncology. The combination of tumour targeting and enhanced activity with existing drugs makes the findings scientifically important.
However, patients should remember that these results come from preclinical research, not human clinical trials. While the study offers genuine hope for future therapies, it is still far too early to know whether the same benefits will be seen in people.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and berry that can prevent cancer, diabetes, and obesity.
For more health information, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing vitamin D supplements could strongly reduce cancer death.
Source: Cleveland Clinic Foundation and Nitric Oxide Services, LLC.
